Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of California, Irvine
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07064018CT.gov Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | — | Recruiting | — | — | — |
NCT06212752CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | — | Active Not Recruiting | — | — | — |
NCT05722015CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | — | Active Not Recruiting | — | — | — |
NCT06958614CT.gov Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC | — | Completed | — | — | — |
NCT02650635CT.gov TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | — | Terminated | — | — | — |
NCT02087176CT.gov A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | — | Terminated | — | — | — |
NCT01933932CT.gov Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC | — | Active Not Recruiting | — | — | — |
NCT01840579CT.gov Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | — | Completed | — | — | — |
NCT01059643CT.gov A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | — | Completed | — | — | — |
NCT00240097CT.gov Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
Show 2 more trialsShow fewer
NCT00291850CT.gov Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA NSCLC | — | Terminated | — | — | — |
NCT00682383CT.gov Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pegfilgrastim (this asset) | University of California, Irvine | Approved | B · 61 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Pegfilgrastim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neutropenia | — | P4 | BBB · 76 |
| Primary Peritoneal Carcinoma | — | P2/3 | BBB · 73 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pegfilgrastim in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pegfilgrastim-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →